A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
Supported projects > Other Supported Projects · 2018
Authors: Tuncay GÖKSEL
2018-2021, Other Supported Projects, R & D Project, Continues